Earli Inc.
AI-powered cancer detection and treatment platform that identifies early-stage cancers through molecular biomarkers and triggers self-destruction mechanisms
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2018
- Latest Form D
- $40M, Jan 2021
- Total capital
- $40M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $40M
- 1 Form D · last Jan 2021
- 69 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 19 pending · first 2024
- Rank in peer group#46 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$40M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#46 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- David SuhyResearcherExecutive Officer, DirectorLinked by 2 patents
- Cyriac RoedingExecutive Officer, DirectorNamed in SEC Form D filings
- Jorge CondeDirectorNamed in SEC Form D filings
- Justin KaoDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 22- PendingNucleic Acid Delivery CompositionsUSPTOApplication 19646336
- PendingNucleic Acid Delivery CompositionsUSPTOApplication 19551454
- PendingSynthetic Cancer-specific PromotersUSPTOApplication 19451370
Show all 22 patent records
- Nucleic Acid Delivery CompositionsJul 30, 2026 · Application 19646336Pending
- Nucleic Acid Delivery CompositionsJul 16, 2026 · Application 19551454Pending
- Synthetic Cancer-specific PromotersMay 21, 2026 · Application 19451370Pending
- Synthetic Cancer-specific PromotersMar 24, 2026 · US 12,582,726Granted
- Methods And Compositions For Synthetic BiomarkersOct 21, 2025 · US 12,448,652Granted
- Synthetic Cancer-specific PromotersMay 22, 2025 · Application 63834389Pending
- Methods Using Surface-expressible Activatable Epitopes To Localize And/or Treat Diseased CellsMay 8, 2025 · Application 18936497Pending
- Methods And Compositions For Synthetic BiomarkersFeb 27, 2025 · Application 18455209Pending
- Methods And Compositions For Synthetic BiomarkersAug 13, 2024 · US 12,060,613Granted
- Methods And Compositions For Synthetic BiomarkersSep 1, 2022 · Application 17494465Pending
- Improved Methods And Compositions For Synthetic BiomarkersApplication PCTUS2020026758Pending
- Improved Methods And Compositions For Synthetic BiomarkersApplication 62955925Pending
- Methods And Compositions For Synthetic BiomarkersApplication 62830279Pending
- Nucleic Acid Delivery CompositionsApplication PCTUS2024044226Pending
- Synthetic Cancer-specific PromotersApplication PCTUS2024038613Pending
- Nucleic Acid Delivery CompositionsApplication 63579480Pending
- Synthetic Cancer-specific PromotersApplication 63532316Pending
- Synthetic Cancer-specific PromotersApplication 63514317Pending
- Methods Using Surface-expressable Activatable Epitopes To Localize And/or Treat Diseased CellsApplication PCTUS2023020892Pending
- Methods Using Surface-expressable Activatable Epitopes To Localize And/or Treat Diseased CellsApplication 63429783Pending
- Methods Using Surface-expressable Activatable Epitopes To Image And/or Treat Disease CellsApplication 63338435Pending
- Improved Methods And Compositions For Synthetic BiomarkersApplication PCTUS2022022603Pending
Related companies, and why
- Nkarta, Inc.Similar federal contract value in Biotech · null in contracts
- GLOBEIMMUNE INCSimilar federal contract value in Biotech · null in contracts
- Liquid BioScience, Inc.Similar federal contract value in Biotech · null in contracts
- Bugworks Research, Inc.Similar federal contract value in Biotech · null in contracts
- Scholar RockSimilar federal contract value in Biotech · null in contracts
- SeaStar Medical, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .